Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia

Purpose The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. Methods This was a multicenter, observational study inclu...

ver descrição completa

Detalhes bibliográficos
Autores: Calleja, José Luis, Delgado, Salvadora, Val, Adolfo del, Hervás, Antonio, Larraona, José Luis, Terán, Álvaro, Colon Cancer Study Group, Argüelles Arias, Federico
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2016
País:España
Recursos:Universidad de Sevilla (US)
Repositório:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/172861
Acesso em linha:https://hdl.handle.net/11441/172861
https://doi.org/10.1007/s00384-015-2461-x
Access Level:Acceso aberto
Palavra-chave:Iron deficiency anemia
Colon cancer surgery
Iron intravenous administration
Ferric carboxymalto
id ES_c8f562ad79bb384b812084d8788d3e37
oai_identifier_str oai:idus.us.es:11441/172861
network_acronym_str ES
network_name_str España
repository_id_str
spelling Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemiaCalleja, José LuisDelgado, SalvadoraVal, Adolfo delHervás, AntonioLarraona, José LuisTerán, ÁlvaroColon Cancer Study GroupArgüelles Arias, FedericoIron deficiency anemiaColon cancer surgeryIron intravenous administrationFerric carboxymaltoPurpose The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. Methods This was a multicenter, observational study includ- ing two cohorts of consecutive CC anemic patients: the no-IV iron treatment group was obtained retrospectively while FCM-treated patients were recorded prospectively. Results A total of 266 patients were included: 111 received FCM (median dose 1000 mg) and 155 were no-IV iron sub- jects. Both groups were similar in terms of demographic char- acteristics, tumor location, surgical approach, and intra- operative bleeding severity. The FCM group showed a signif- icant lower need for red blood cell (RBC) transfusion during the study (9.9 vs. 38.7 %; OR: 5.9, p<0.001). In spite of lower hemoglobin levels at baseline diagnosis and lower transfusion rates in the FCM group, the proportion of responders was significantly higher with respect to the no-IV group both at hospital admission (48.1 vs. 20.0 %, p<0.0001) and at 30 days post-surgery (80.0 vs. 48.9 %, p<0.0001). The percentage of patients with normalized hemoglobin levels was also higher in the FCM group (40.0 vs. 26.7 % at 30 days, p<0.05). A lower number of reinterventions and post-surgery complications were seen in the FCM group (20.7 vs. 26.5 %; p=0.311). The FCM group presented a significant shorter hospital stay (8.4±6.8 vs. 10.9±12.4 days to discharge; p<0.001). Conclusions Preoperative ferric carboxymaltose treatment in patients with CC and iron deficiency anemia significantly re- duced RBC transfusion requirements and hospital length of stay, reaching higher response rates and percentages of nor- malized hemoglobin levels both at hospital admission and 30 days post-surgery.SpringerMedicina2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/172861https://doi.org/10.1007/s00384-015-2461-xreponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésInternational Journal of colorectal disease, 31, 543-551.https://link.springer.com/article/10.1007/s00384-015-2461-x#citeasinfo:eu-repo/semantics/openAccessoai:idus.us.es:11441/1728612026-06-17T12:51:07Z
dc.title.none.fl_str_mv Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
title Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
spellingShingle Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
Calleja, José Luis
Iron deficiency anemia
Colon cancer surgery
Iron intravenous administration
Ferric carboxymalto
title_short Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
title_full Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
title_fullStr Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
title_full_unstemmed Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
title_sort Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
dc.creator.none.fl_str_mv Calleja, José Luis
Delgado, Salvadora
Val, Adolfo del
Hervás, Antonio
Larraona, José Luis
Terán, Álvaro
Colon Cancer Study Group
Argüelles Arias, Federico
author Calleja, José Luis
author_facet Calleja, José Luis
Delgado, Salvadora
Val, Adolfo del
Hervás, Antonio
Larraona, José Luis
Terán, Álvaro
Colon Cancer Study Group
Argüelles Arias, Federico
author_role author
author2 Delgado, Salvadora
Val, Adolfo del
Hervás, Antonio
Larraona, José Luis
Terán, Álvaro
Colon Cancer Study Group
Argüelles Arias, Federico
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv Iron deficiency anemia
Colon cancer surgery
Iron intravenous administration
Ferric carboxymalto
topic Iron deficiency anemia
Colon cancer surgery
Iron intravenous administration
Ferric carboxymalto
description Purpose The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. Methods This was a multicenter, observational study includ- ing two cohorts of consecutive CC anemic patients: the no-IV iron treatment group was obtained retrospectively while FCM-treated patients were recorded prospectively. Results A total of 266 patients were included: 111 received FCM (median dose 1000 mg) and 155 were no-IV iron sub- jects. Both groups were similar in terms of demographic char- acteristics, tumor location, surgical approach, and intra- operative bleeding severity. The FCM group showed a signif- icant lower need for red blood cell (RBC) transfusion during the study (9.9 vs. 38.7 %; OR: 5.9, p<0.001). In spite of lower hemoglobin levels at baseline diagnosis and lower transfusion rates in the FCM group, the proportion of responders was significantly higher with respect to the no-IV group both at hospital admission (48.1 vs. 20.0 %, p<0.0001) and at 30 days post-surgery (80.0 vs. 48.9 %, p<0.0001). The percentage of patients with normalized hemoglobin levels was also higher in the FCM group (40.0 vs. 26.7 % at 30 days, p<0.05). A lower number of reinterventions and post-surgery complications were seen in the FCM group (20.7 vs. 26.5 %; p=0.311). The FCM group presented a significant shorter hospital stay (8.4±6.8 vs. 10.9±12.4 days to discharge; p<0.001). Conclusions Preoperative ferric carboxymaltose treatment in patients with CC and iron deficiency anemia significantly re- duced RBC transfusion requirements and hospital length of stay, reaching higher response rates and percentages of nor- malized hemoglobin levels both at hospital admission and 30 days post-surgery.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/172861
https://doi.org/10.1007/s00384-015-2461-x
url https://hdl.handle.net/11441/172861
https://doi.org/10.1007/s00384-015-2461-x
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv International Journal of colorectal disease, 31, 543-551.
https://link.springer.com/article/10.1007/s00384-015-2461-x#citeas
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419330459926528
score 15,228081

Registros relacionados